

Refine Search

Search Results

Terms	Documents
L19 and L22	2

Database:

US Pre-Grant Publication Full-Text Da
US Patents Full-Text Database
US Patents OCR Backfile
EPO Abstracts Database
JPO Abstracts Database
Derwent World Patents Index

Search Type: ☒ Prior Art ☐ Interference

Search:

L24

Refine Search

Recall Text

Clear

Interrupt

Search History

DATE: Friday, July 31, 2009

[Purge Queries](#)[Printable Copy](#)[Create Case](#)

Set Name Query
Side by Side

Hit Count Set Name
Result Set

Set Name
Grid

Prior Art Searches

DB=PGPB,USPT,EPAB,JPAB,DWPI; PLUR=NO; OP=ADJ

<u>L24</u>	L19 and L22	2	<u>L24</u>	<u>L24</u>
<u>L23</u>	L21 and L22	22	<u>L23</u>	<u>L23</u>
<u>L22</u>	(administer\$) with (EPO or erythropoietin)	2255	<u>L22</u>	<u>L22</u>
<u>L21</u>	L17 and L20	66	<u>L21</u>	<u>L21</u>

<u>L20</u>	(endothelial) with (progenitor)	3987	<u>L20</u>	<u>L20</u>
<u>L19</u>	L17 and L18	4	<u>L19</u>	<u>L19</u>
<u>L18</u>	(dysfunct\$ or damage\$ or necro\$ or apopto\$) with (endothelial progenitor)	51	<u>L18</u>	<u>L18</u>
<u>L17</u>	L15 and L16	2958	<u>L17</u>	<u>L17</u>
<u>L16</u>	(hypertension or hypercholest\$ or ADMA or insulin resistance or hyperhomostein\$ or asymmetric dimethylarginine)	104919	<u>L16</u>	<u>L16</u>
<u>L15</u>	(end organ damage) or (organ failure) or (organ damage)	8863	<u>L15</u>	<u>L15</u>
<u>L14</u>	L1 and L13	1	<u>L14</u>	<u>L14</u>
<u>L13</u>	(bahlmann or haller).in.	3129	<u>L13</u>	<u>L13</u>
<u>L12</u>	L7 and L11	2	<u>L12</u>	<u>L12</u>
<u>L11</u>	L3 and L10	13	<u>L11</u>	<u>L11</u>
<u>L10</u>	(hypertension or hypercholesterolemia or ADMA or insulin resistance or hyperhomostein\$)	101715	<u>L10</u>	<u>L10</u>
<u>L9</u>	L3 and L7	2	<u>L9</u>	<u>L9</u>
<u>L8</u>	L6 and L7	1	<u>L8</u>	<u>L8</u>
<u>L7</u>	(end organ damage) or (organ failure)	6397	<u>L7</u>	<u>L7</u>
<u>L6</u>	L3 and L5	6	<u>L6</u>	<u>L6</u>
<u>L5</u>	(cardiovascular) with (risk\$ or risk factor\$)	11508	<u>L5</u>	<u>L5</u>
<u>L4</u>	(L3) and (cardiovascular risk\$ or cardiovascular risk factor\$)	6	<u>L4</u>	<u>L4</u>
<u>L3</u>	(dysfunct\$ or damage\$ or necro\$ or apopto\$) with (endothelial progenitor cell\$)	50	<u>L3</u>	<u>L3</u>
<u>L2</u>	(dysfunct\$) with (endothelial progenitor cell\$) and (cardiovascular risk\$ or cardiovascular risk factor\$)	3	<u>L2</u>	<u>L2</u>
<u>L1</u>	(endothelial progenitor cell\$) and (cardiovascular risk\$) and (end organ damage or organ failure)	1	<u>L1</u>	<u>L1</u>

END OF SEARCH HISTORY

